Chief Executive Officer resigns
6A884712_PAA
PharmAust Appendix 4C and Shareholders Update (Q3, 2018 FY)
180501_4C and Shareholders Update_March
PharmAust enters option to license agreement with Elanco for dog cancer treatment
180418_Elanco PharmAust Agreement
Trading Halt
180416_Trading Halt
Wayne Best appointed Epichem Chairman and Dr Keenan as CEO
180410_Epichem New CEO_final
SECONDARY TRADING NOTICE PURSUANT TO SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001
180320_Cleansing Notice
Appendix 3B: New issue announcement, application for quotation of additional securities and agreement
180316_Appendix 3B and 3Y Notice
Appendix 3Y: Change of Director’s Interest Notice
180316_Change in Directors Interests
PharmAust new collaboration with leading cancer research institute on its MPL drug candidate
180312_PAA_ONJCRI collaboration_(clean)